MicroBiome Therapeutics (formerly NuMe Health) announced positive top-line results from the company’s clinical trial of their lead product, a microbiome modulator being developed for type 2 diabetes and prediabetes. The modulator is designed to improve glucose tolerance in diabetic patients by shifting the gastrointestinal (GI) microbiome.

February 18, 2014 – Read more at The Pharma Letter